Rituximab in combination with adapted-dose of ifosfamide and etoposide as salvage treatment in elderly refractory/relapsed diffuse large B-cell lymphoma patients non-candidate for high dose therapy: a retrospective study.
Aged
Antineoplastic Combined Chemotherapy Protocols
/ adverse effects
Etoposide
/ adverse effects
Humans
Ifosfamide
/ adverse effects
Lymphoma, Large B-Cell, Diffuse
/ diagnosis
Lymphoma, Non-Hodgkin
/ drug therapy
Retrospective Studies
Rituximab
/ adverse effects
Salvage Therapy
Transplantation, Autologous
Treatment Outcome
Diffuse large B-cell lymphoma
refractory
relapse
rituximab–ifosfamide–etoposide
salvage therapy
transplantation-ineligible
Journal
Leukemia & lymphoma
ISSN: 1029-2403
Titre abrégé: Leuk Lymphoma
Pays: United States
ID NLM: 9007422
Informations de publication
Date de publication:
03 2022
03 2022
Historique:
pubmed:
2
11
2021
medline:
15
4
2022
entrez:
1
11
2021
Statut:
ppublish
Résumé
We retrospectively reviewed for 72 relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) patients ineligible for autologous stem-cell transplantation (ASCT) treated between 2004 and 2017, efficacy and safety profile of rituximab (375 mg/m
Identifiants
pubmed: 34720034
doi: 10.1080/10428194.2021.1998483
doi:
Substances chimiques
Rituximab
4F4X42SYQ6
Etoposide
6PLQ3CP4P3
Ifosfamide
UM20QQM95Y
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM